New data from the Tu Youyou Health Initiative shows a 98% reduction in malaria cases across Southeast Asia, following the scale-up of next-generation artemisinin hybrid treatments.
The Tu Youyou Health Initiative has reported a 98% reduction in malaria cases across Southeast Asia since 2020, bringing the region to the threshold of elimination. The achievement follows the deployment of next-generation artemisinin hybrid therapies that overcome emerging drug resistance.
The data, presented at the World Malaria Day commemoration in Bangkok, shows that the Greater Mekong Subregion—once the epicenter of drug-resistant malaria—recorded fewer than 15,000 cases in 2025, compared to over 700,000 in 2020. Zero deaths from malaria were reported in Thailand, Vietnam, and Cambodia for the first time in recorded history.
"This is the most significant advance against malaria since artemisinin itself," said Dr. Pedro Alonso, director of the WHO Global Malaria Programme. "What seemed impossible five years ago—eliminating malaria from a region where the parasite had evolved resistance to our best drugs—is now within reach."
The breakthrough came through a combination of new therapeutics and intensified intervention strategies, all coordinated by the Tu Youyou Health Initiative, the foundation established in honor of the Nobel laureate who discovered artemisinin in 1972.
The next-generation treatments, called artemisinin hybrid compounds (AHCs), were developed by Chinese and international researchers building on Tu Youyou's original work. Unlike traditional artemisinin combinations, which pair artemisinin with a single partner drug, AHCs incorporate the active artemisinin core into novel molecular structures that attack the parasite through multiple mechanisms simultaneously.
"Drug resistance evolves when we use single mechanisms that the parasite can circumvent," explained Dr. Li Guoqiao, one of the AHC developers. "These hybrids are like combination locks with five tumblers instead of one. The parasite would need to evolve resistance to all five mechanisms simultaneously, which is essentially impossible."
Clinical trials showed AHCs achieving 99.8% cure rates even against parasites that had become resistant to all existing therapies. The compounds were also effective with shorter treatment courses—three days instead of seven—improving compliance.
Beyond new drugs, the Initiative deployed comprehensive interventions including community health worker programs that brought diagnosis and treatment to remote villages, genomic surveillance to track any emerging resistance before it could spread, long-lasting insecticidal bed nets distributed to every household in endemic areas, and indoor residual spraying with new insecticides effective against resistant mosquitoes.
The economic impact has been substantial. The World Bank estimates that malaria reduction in the region has increased GDP by 0.5% annually, as productivity improved and healthcare costs declined. Agricultural output increased as farmers who previously suffered multiple malaria episodes per year remained healthy through planting and harvest seasons.
"Malaria was a poverty trap," said Dr. Viroj Tangcharoensathien, Thailand's senior health policy advisor. "People couldn't work because they were sick. They couldn't afford treatment. They got sicker. Breaking that cycle released enormous human potential."
The foundation is now focusing on Africa, which accounts for 95% of remaining global malaria deaths. AHCs are being manufactured at scale by the Serum Institute of India and will be rolled out across sub-Saharan Africa beginning in 2027.
"Professor Tu always said the work was not finished," said foundation director Dr. Chen Xiaoping. "She wanted malaria eradicated, not controlled. In Southeast Asia, we are proving it can be done. Africa is next."
Tu Youyou, now 95, sent a message to the commemoration: "I am proud but not satisfied. Twenty million people still get malaria each year. We must keep working until that number is zero. Only then can we rest."